MVP and KPNA2

  • Number of citations of the paper that reports this interaction (PMID 21988832)
  • 14
  • Data Source:
  • BioGRID (two hybrid)

MVP

KPNA2

Gene Name major vault protein karyopherin alpha 2 (RAG cohort 1, importin alpha 1)
Image
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 57 interactors: ADAMTSL4 AES BANP BZRAP1 C1orf94 CALCOCO2 CAMK2B CCDC36 CKAP4 CYTB DISC1 DLX2 EPHX2 ESR1 FAM154A FAM46C GIT2 GOLGA2 HP KCTD9 KPNA2 KPNA3 MDFI MEOX1 MEOX2 MID2 MKL1 NNT NOTCH2NL OBFC1 PARP4 PIH1D2 PLSCR1 POT1 PSTPIP1 PTEN PTPN11 RAB3IP RBPMS REL RHOXF2 RIMBP3 RNF111 SERTAD1 SKIL SLC2A4 TCF4 TFCP2 TP53 TRAF2 TRIM27 TRIM42 TRIP13 TRIP6 VAC14 ZBTB32 ZMIZ2 104 interactors: ACTN1 ACTN4 ANKIB1 AP2B1 APOBEC1 APP ARL4A ARL5A BRCA1 BTBD2 CASP2 CCDC107 CDA CDK5RAP3 CHD3 CHEK2 CORO1B CREB3L3 CREBBP CSE1L CSNK1A1 CUL4B DCTN2 DDIT3 EP300 EPB41 FEZ2 FN1 FTH1 GART GMCL1 GRB2 H1F0 HAP1 HMG20A HNRNPC HOMER2 HOMEZ HSPA4 IFT20 IMMT INO80E ITK JUN KLC4 KPNB1 KRT18 KRT40 KRT8 LAMB2 LEF1 LZTS2 MAGED1 MAGEH1 MDFI MLH1 MORC3 MVP MYC NECAB2 NFKBIB NMNAT1 NR3C1 NUP153 NUP50 NUP62 NUTM1 PAX5 PLAG1 PNMA5 PRKD3 PTMA RAG1 RAN RANBP2 RBM48 RBPMS RECQL RELA RELB RGL2 RILP RNMT SART3 SERTAD3 SGK1 SLC2A2 SPRY1 SRPK1 TADA2A TAF3 TAF8 TANK TBPL2 TP53 TRAF1 TRIM54 TSC22D4 TXNIP UBR5 USHBP1 ZBTB7B ZC3H12A ZNF131
Entrez ID 9961 3838
HPRD ID 05475 02818
Ensembl ID ENSG00000013364 ENSG00000182481
Uniprot IDs B4DP93 Q14764 P52292 Q7Z726
PDB IDs 1Y7X 1EFX 1QGK 1QGR 3FEX 3FEY 4E4V
Enriched GO Terms of Interacting Partners?
Tagcloud ?
afp  bleomycin  bronchogenic  cap  chance  cisplatin  cooperative  crs  cyclophosphamide  doxorubicin  eastern  ecog  efficacious  entered  est  evaluable  fluorouracil  institution  lethal  mitomycin  modest  nscbc  october  oncology  prs  regimens  shrinkage  threatening  vinblastine 
aggressive  aggressiveness  assembled  attempt  carcinomas  curable  diagnostics  disregarding  eic  emgd  endometrial  entities  figo  immunoreactivity  interplay  introducing  malignancy  mediator  mfe  microarrays  nucleocytoplasmic  precancerous  regimens  surgically  tmas  trp53  tumour  untreatable  uterus 
Tagcloud (Difference) ?
afp  bleomycin  bronchogenic  cap  chance  cisplatin  cooperative  crs  cyclophosphamide  doxorubicin  eastern  ecog  efficacious  entered  est  evaluable  fluorouracil  institution  lethal  mitomycin  modest  nscbc  october  oncology  prs  shrinkage  threatening  vinblastine 
aggressive  aggressiveness  assembled  attempt  carcinomas  curable  diagnostics  disregarding  eic  emgd  endometrial  entities  figo  immunoreactivity  interplay  introducing  malignancy  mediator  mfe  microarrays  nucleocytoplasmic  precancerous  surgically  tmas  trp53  tumour  untreatable  uterus 
Tagcloud (Intersection) ?
regimens